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Abstract DHEA (3β-hydroxy-androst-5-en-17-one) is a nat-
ural steroid prohormone. Despite a lack of information on the
effect, DHEA and other prohormones are frequently used as a
food supplement by body-builders. DHEA is suspected for
growth promoting abuse in cattle as well. Considering the latter,
urine samples from a previous exposure study in which calves
were exposed to 1 g DHEA per day for 7 days, were used. The
calves were divided in three groups: one orally treated, one
intramuscularly injected, and a control group. The effect of this
treatment on the urinary profile of several precursors and
metabolites of DHEA was investigated. Urine samples were
collected several days before and during the 7 days of
administration and were submitted to a clean-up procedure
consisting of a separation of the different conjugates (free,
glucuronidated, and sulfated forms) of each compound on a
SAX column (Varian). An LC-MS/MS method was developed
for the detection and quantification of several metabolites of the
pathway of DHEA including 17α- and 17β-testosterone, 4-
androstenedione, 5-androstenediol, pregnenolone, and hydrox-
ypregnenolone. Elevated levels of DHEA, 5-androstenediol,
and 17α-testosterone were observed in the free and sulfated
fraction of the urine of the treated calves, thus indicating that the
administered DHEA is metabolized mainly by the ∆5-pathway
with 5-androstenediol as the intermediate. Sulfoconjugates of
DHEA and its metabolites were found to constitute the largest
proportion of the urinary metabolites. The free form was also
present, but in a lesser extent than the sulfated form, while
glucuronides were negligible.
Keywords LC-MS/MS . DHEA .Metabolites .
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Introduction
The EC Directive 96/22 states that substances with hormonal
activity are prohibited in cattle fattening [1]. Monitoring
programs are required to live up to this Directive, thus
requiring experience in analyzing feed, urine, and tissue
samples for screening and confirmation of hormone residues
[19]. In addition, knowledge about absorption, biotransfor-
mation and excretion kinetics of illegally administered
hormonal substances, as well as levels of endogenous
hormones in livestock, is another requisite [1, 18]. Besides
steroids, there is a tendency in the livestock production
towards misuse of feed supplements and preparations
containing prohormones. The action of these prohormones
is based on the conversion into more active hormones in
target organs, after administration and uptake in the blood
circulation. This may lead to anabolic action and subse-
quently improved lean/fat ratios in farm animals [16, 17].
Dehydroepiandrosterone (DHEA, 3β-hydroxy-androst-5-
en-17-one) is a natural steroid prohormone and is a key
intermediate in the biosynthesis of biologically potent andro-
gens and estrogens [14, 15]. Endogenous steroids can be
produced by the means of two alternative pathways, the ∆4-
and the ∆5-pathway, corresponding to the metabolization of
cholesterol to pregnenolone and progesterone as the primary
precursors and, respectively, 4-androstenedione and DHEA
as their intermediates. Starting from DHEA, the conversion
to 17β-testosterone (Fig. 1) can be catalyzed by hydroxyste-
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roid dehydrogenases (HSDs) over 4-androstenedione (main-
ly in the gonads) or 5-androstenediol (mainly in the adrenal
gland) [11–13, 16]. However, abuse of DHEA, and also
other prohormones, has been hard to prove due to the
incomplete understanding of the DHEA metabolism as well
as intra- and interindividual variability in urinary steroid
excretion [10, 17]. Recently, a metabolomics-based screen-
ing strategy has been conducted by Rijk et al. [9] in which
several bovines where treated with prohormones such as
DHEA and pregnenolone. Data were analyzed using
multivariate statistics followed by identification of signals
differential in urine of DHEA-treated versus control animals.
This screening strategy is a useful tool to trace abuse with
prohormones like DHEA and pregnenolone. However, the
concentration levels of these prohormones remain unknown
and therefore a targeted analysis after this untargeted
approach can be an added value.
The aim of our study was to focus on the excretion profile of
DHEA and its metabolites in calf urine after an oral and
intramuscular administration of DHEA. It was possible with
our quantitative method to get an idea of the concentration
levels of DHEA and several of its metabolites after intake of
DHEA, which was unknown in calves until now. Naturally,
DHEA is mainly present in blood and urine of older animals in
its sulfated form and to a much lesser extent in its free form or
as a glucuronide conjugate [10]. The sample clean-up was set
up such that each form, i.e., free, sulfated, or glucuronidated
form of DHEA and its metabolites could be investigated.
Materials and methods
Experimental protocol
Urine samples were collected according to the study design
presented in Fig. 2. Eight calves ranging in age from 6 until
10 months were used in this study, aiming to simulate the
actual practice. These real-life bovines were housed in
stables and normally fed. At two different time intervals,
several calves were allocated to a group and received either
an oral treatment with DHEA or an intramuscular treatment
with DHEA, while others served as controls. Treated calves
were administered with 1 g of DHEA, orally or intramus-
cularly, every day for 7 days. In the first period (June
2005), one calf was treated orally, one intramuscularly, and
three served as controls and did not receive any DHEA
supplementation. In the second period (December 2006),
one calf was treated orally, one intramuscularly, and one
served as a control. DHEA treatment was performed in the
morning and urine sampling in the late afternoon for the
first period and just before the next treatment in the second
group (period 2). Urine samples were collected several days
before treatment (5 days before treatment in period 1 and
on days −20 and −5 before treatment in period 2) and
during 7 days of administration in both periods. This study
was undertaken after approval by the Ethical Committee of
Ghent University. Samples were collected and frozen at
−20 °C until analysis.
Reagents and chemicals
Methanol was high-performance-liquid-chromatography-
grade and obtained from VWR International (Zaventem,
Belgium). Ethyl acetate was purchased from Acros Organics
(Geel, Belgium), diethylamine from Sigma-Aldrich and Helix
pomatia digestive juice (Cat. No. 127 698; β-glucuronidase
activity: 4.5 standard units; arylsulfatase activity: 14 standard
units) from Boehringer Mannheim (Mannheim, Germany).
Water was obtained from a Milli-Q Gradient System
(Millipore, Bedford, MA, USA). Sodium acetate, glacial
acetic acid, formic acid, fuming hydrochloric acid 37%,
lithium chloride (pro analysis) were purchased from Merck
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(Overijse, Belgium). Standards of dehydroepiandrosterone
(DHEA), 4-androstene-3,17- dione (AED), 17α-testosterone
(α-T), 17β-testosterone (β-T), and pregnenolone (Preg)
were purchased from Sigma-Aldrich, while 17α-
hydroxypregnenolone (OH-Preg) and 5-androstene-3β,17β-
diol (5-Andro) were obtained from Steraloids (Newport, RI,
USA). 17β-19-Nortestosterone-D3 (NT-D3) and 17α-
methyltestosterone-D3 (MT-D3) were supplied by RIVM
(Bilthoven, The Netherlands). Miglyol 812 (Certa SA,
Braine-l’Alleud, Belgium) was used for dissolving the
DHEA for intramuscular injection.
Preparation of standard solutions
Stock standard solutions (1 mg mL−1) of α-T, β-T, AED, 5-
Andro, Preg, OH-Preg, and DHEA were prepared by
dissolving 5.0 mg in 5.00 mL of methanol. Stock standard
solutions of NT-D3 and MT-D3 were prepared from
ampoules containing 0.1 mg of lyophilized powder by
adding 1.00 mL of methanol to the ampoules, vortexing,
and transferring the methanol into a glass tube giving
standard solutions of 0.1 mg mL−1. Stock solutions were
stored at 4 °C and had a shelf-life of at least 1 year.
Working standard solutions are prepared by dilution with
methanol to the appropiate concentrations of 10 and 1 ng
µL−1 and stored at 4 °C for maximum 3 months. From the
individual stock standard solutions different standard
mixtures were prepared and stored at 4 °C for 3 months.
These standard mixtures were used to create a matrix
calibration curve.
Materials and apparatus
Octadecyl (C18; 6 mL, 500 mg) and aminopropyl (NH2;
3 mL, 500 mg) SPE columns were purchased from Grace
Discovery Sciences (Lokeren, Belgium). The C18-SPE
column was conditioned by passing through 2×5 mL of
methanol followed by 2×5 mL of water. The NH2-SPE
column was conditioned by passing through 2×3 mL
ethylacetate. Bond Elut strong anion exchange (SAX)
SPE columns were obtained from Varian (Sint-Katelijne
Waver, Belgium). The SAX column was conditioned by
subsequently passing 4 mL methanol, 4 mL water, 20 mL
of 0.5 M acetic acid in water, 20 mL of water and 5 mL of
methanol.
Analysis were performed on a Alliance 2695 HPLC
system instrument coupled to a Quattro LCZ mass
spectrometer (both from Waters, Milford, MA, USA)
equipped with the Masslynx software for data processing.
Chromatographic separation was achieved on a Symmetry
C18 column (2.1×150 mm, 5 µm) preceded by a guard
column Symmetry C18 (2.1×10 mm, 3.5 µm; both from
Waters, Milford, MA, USA). The column was kept at room
temperature (20–23 °C). The mobile phase consisted of
water/MeOH/ formic acid (FA) (89.7:10:0.3) and MeOH/
FA (99.7/0.3) using the gradient elution program described
in Table 1. The injection volume was 100 µL.
The MS/MS operating parameters were obtained and
optimized under positive-ion (ESI+) mode. Multiple reac-
tion monitoring (MRM) transitions for each analyte were
individually optimized, an overview of the precursor and
Fig. 2 Study design
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product ions used in this MRMmethod, together with the cone
voltages and collision energies, is given in Table 2. Capillary
voltage was set at 4.8 kV, the extractor at 3 V and high-purity
nitrogen was used as spray gas. Source and desolvation
temperatures were set at 150 and 350 °C, respectively.
Separation of the free, glucuronide, and sulfate fractions
The sample clean-up was based on the method descibed by
Van Poucke et al. for the fractionation of free and
conjugated steroids for the detection of boldenone metab-
olites in calf urine [8]. In short, the procedure is as follows:
the pH of 10 mL of the urine samples were adjusted to 4.6
with 3 M acetate buffer (pH 4.6) and applied onto C18
cartridges. After washing with 2×5 mL of water and 2×
5 mL 10% methanol, a preconditioned SAX column was
placed under the C18 column. The free and conjugated
fractions were then eluted with 2×5 mL methanol where
only the conjugated fractions were retained and the free
form was collected. Next, the glucuronide fraction was
eluted from the SAX column with 10 mL FA (0.5 M) in
methanol. In the third step, a preconditioned C18 cartridge
was placed underneath the SAX column and the sulfate
fraction was eluted from the SAX column with 10 mL
triethylamine (0.5 M) in water and was trapped onto the C18
column. After washing the C18 column with 2×5 mL water,
the suphate fraction was finally eluted with 5 mL of
methanol. All fractions were then evaporated to dryness at
40 °C under nitrogen.
Hydrolysis
Next, the glucuronide and sulfate fractions were submitted
to an hydrolysis step. The enzymatic hydrolysis of the
glucuronide fractions was achieved by adding 5 mL of a
0.2 M acetate buffer (pH 4.6) and 25 µL of a tenfold
dilution of Helix pomatia juice in water. The samples were
then kept for 2 h at 60 °C. For the hydrolysis of the sulfate
fraction, the dried residue was dissolved in 5 mL of a
solvolysis solution consisting of 1 M lithium chloride/
hydrochloric acid. This samples were kept 1 h at 80 °C and
afterwards 15 mL of water was added and the samples were
centrifuged at 2,800×g.
Table 2 Precursor and product ions
Compound Precursor ion (m/z) Molecular ion Cone voltage (V) Product ion (m/z) Collision energy (eV)
T (α and β) 289.4 [M+H]+ 18 109.1a 33
97.1
DHEA 253.4 [M+H-2H2O]
+ 25 225.0 15
197.0a 17
AED 287.2 [M+H]+ 36 109.3a 18
97.2
5-Andro 273.4 [M+H-H2O]
+ 27 255.3a 10
159.2 12
Preg 317.3 [M+H]+ 24 281.4a 15
255.3 13
OH-Preg 333.2 [M+H]+ 22 297.6a 10
133.2 18
MT-D3 306.0 [M+H]
+ 50 109.0a 30
97.0
NT-D3 278.0 [M+H]
+ 45 109.0a 28
83.0
Cone voltages and collision energies for each transition monitored in MRM (ESI+) analysis
aMost abundant product ion
Table 1 Gradient elution program for the separation of the precursors
and metabolites of DHEA
Time(min) Flow rate (mL min−1) %A %B Curve
0 0.3 45 55 Initial
1 0.3 45 55 1
8 0.3 40 60 9
13 0.3 40 60 1
14 0.3 0 100 6
22 0.3 0 100 1
23 0.3 45 55 6
30 0.3 45 55 1
A water/MeOH/FA (89.7/10/0.3), B MeOH/FA (99.7/0.3)
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Final sample clean-up
The dried residue of the free fraction was redissolved in
10 mL of water. The free fractions and the supernatant
of the glucuronide and sulfate fractions were then
applied onto a C18 column. Afer washing with 2×5 mL
of water and 2×5 mL 10% methanol, the column was
dried and placed underneath a preconditioned NH2
column. The columns were then eluted with 5 mL of
ethyl acetate. The eluates were evaporated to dryness at
40 °C under nitrogen. The dried residues were each
dissolved in 150 µL of mobile phase (methanol/water/FA
(60/39.7/0.3)).
Quantification and identification
Matrix calibration curves were performed daily by
analyzing five blank urines (10 mL) spiked at five
different levels in the 1–80 ng mL−1 range for α-T, β-T,
AED, OH-Preg, and Preg, the 1–200 ng mL−1 range for 5-
Andro, and the 1-1,000 ng mL−1 range for DHEA. All urine
samples were spiked with MT-D3 at a concentration level of
2 ng mL−1 as an internal standard. The final extracts from
treated calves were diluted ten times with the mobile phase
and the external NT-D3 standard was added at the end of
the analysis at a concentration of 2 ng mL−1. Diluted
extracts of urine samples were only used to quantify the
Table 4 Basal urinary concentrations (free and sulfated form) of DHEA and its metabolites of the calves included in group 2 before treatment
n Mean ± SE (ng mL−1) Median (ng mL−1) Minimum (ng mL−1) Maximum (ng mL−1)
Free form of
DHEA 7 0.0±0.0 0.0
0.0
0.0
5-Andro 7 0.0±0.0 0.0
0.0
0.0
α-T 7 0.3±0.4 0.0
0.0
0.8
β-T 7 0.2±0.3 0.0
0.0
0.5
AED 7 0.4±0.2 0.5
0.0
0.5
Sulfated form of
DHEA 6 43.9±49.1 23.1
11.8
138.2
5-Andro 6 70.2±63.9 69.8
0.0
158.7
α-T 6 72.2±49.5 57.6
15.5
134.0
β-T 6 8.4±7.2 6.9
1.5
22.2
Table 3 Basal urinary concentrations (free and sulfated form) of DHEA and its metabolites of the calves included in group 1 before treatment
n Mean±SE (ng mL−1) Median (ng mL−1) Minimum (ng mL−1) Maximum (ng mL−1)
Free form of
DHEA 24 0.0±0.0 0.0 0.0 0.0
5-Andro 24 0.3±0.9 0.0 0.0 3.9
α-T 24 0.7±0.9 0.5 0.0 4.9
β-T 24 0.1±0.2 0.0 0.0 0.5
AED 24 0.4±0.3 0.5 0.0 1.3
Sulfated form of
DHEA 26 45.6±40.7 40.8 4.2 131.4
5-Andro 26 29.9±32.6 21.3 0.0 132.9
α-T 26 9.1±11.9 3.2 0.0 39.6
β-T 26 2.5±4.3 0.4 0.0 16.5
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samples that did not fit in the linear range of the calibration
curve.
Calibration plots were constructed by applying the least-
squares-regression model and by plotting the response
against the hormone concentration. Compounds were only
used in the data analysis when the criteria of the
Commission Decision 2002/657/EC were fulfilled [7] .
Several urines were analyzed on two different time
intervals. The concentrations of all target compounds in
the entire concentration range differed maximally 30%.
Data analysis
All results are reported as the mean ± SE (standard deviation)
and the median. Data were analyzed using a two-way analysis
of variance. Non-parametric data were analyzed by means of
Kruskal–Wallis test. When significant effects were revealed or
only two groups were examined, an independent t test or
Mann–Whitney test taking account of the Bonferroni
correction was used to locate the pair wise differences
between groups. Spearman’s correlations coefficients were
calculated to determine significant correlations between the
concentration of the several hormones and the day of urine
collection. p<0.05 was considered as statistically significant.
All calculations were executed in Excel® or in SPSS®.
Results and discussion
Urinary concentrations of DHEA, AED, 5-Andro, α-T, β-T,
Preg, and OH-Preg in calves were investigated before starting
the treatment and during the DHEA treatment. Levels of the
precursors Preg and OH-preg in urines during the entire study
were found too low to be confirmed and/or quantified.
Therefore, it is not possible to draw any conclusion about
the levels of Preg and OH-Preg before and after treatment with
DHEA and as a consequence the data and statistical
processing of these compounds are left out of the discussion.
Table 3 shows the mean basal concentrations, the median,
minimum, and maximum values of the target analytes in the
urines from the five calves of group 1 (June 2005) before
starting the treatment. This was evaluated in order to show
whether the treated calves were not calves which already
excreted higher concentrations of these hormones and which
statistically did not differ from the control calves at the
beginning of the treatment. No significant differences were
observed in group 1 in the baseline levels of DHEA and its
metabolites 5-Andro, α-T, β-T, AED in the free or sulfated
form. Group 2 (December 2006) did not yield enough data
to prove this statistically. However, the assumption was
made that there was also no significant difference in the
basal urinary concentrations of these hormones in the three
Table 5 Urinary concentrations (free and sulfated form) of DHEA and its metabolites of the control animals before and during the period of
treatment
Before or during treatment n Mean±SE
(ng mL−1)
Median
(ng mL−1)
Minimum
(ng mL−1)
Maximum
(ng mL−1)
Free form of
DHEA Before 17 0.0±00 0.0 0.0 0.0
During 29 0.3±0.6 0.0 0.0 2.4
5-Andro Before 17 0.4±1.1 0.0 0.0 3.9
During 29 0.1±0.6 0.0 0.0 3.2
α-Ta Before 14 1.0±1.2 0.6 0.0 4.9
During 29 0.6±0.6 0.5 0.0 1.6
β-Ta Before 14 0.2±0.2 0.0 0.0 0.5
During 29 0.3±0.4 0.0 0.0 1.0
AED Before 17 0.5±0.3 0.5 0.0 1.3
During 29 1.4±2.9 0.5 0.0 18.4
Sulfated form of
DHEA Before 17 43.2±36.1 42.5 6.2 131.4
During 29 51.1±46.7 34.7 0.0 171.4
5-Andro Before 17 28.1±31.2 15.7 0.0 118.8
During 29 75.8±63.7 72.4 0.0 215.9
α-Ta Before 15 7.6±10.0 2.6 0.0 32.1
During 29 12.7±15.4 4.8 0.0 47.1
β-Ta Before 15 1.5±2.6 0.3 0.0 9.9
During 29 1.1±2.9 0.1 0.0 13.8
a Includes only data from group 1
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calves of group 2, shown in Table 4. Despite the large inter-
and intravariability in all hormones in free and sulfated form,
initial basal levels were not statistically different and within
the normal range. Therefore, the biological variability is not
expected to give any problems when comparing the control
group with the treatment group during the study. However,
when comparing the mean concentrations and corresponding
standard deviations of the two groups (Tables 3 and 4),
slightly higher concentrations of the sulfated form of 5-
Andro, α-T and β-T were observed in group 2. This was
expected as the age of the calves differs between the two
groups and was part of the general idea of using real-life
bovine animals. In group 1, the calves were only 6 months
old in contrast with the calves of group 2 that were already 9
until 10 months of age. These observed differences were
checked statistically. Therefore, basal urinary concentrations
of all the hormones in free and sulfated form before
treatment were compared between groups 1 and 2. A
statistically significant difference in the levels of sulfated
α-T (p=0.027) and β-T (p=0.012) was found between
group 1 and 2. These results, higher levels of α-T and β-T in
group 2, are in accordance with results earlier obtained by
analyzing urine samples of calves and young bovines [6, 18].
These studies pointed out that when the two isomers of
testosterone (α and β) were followed, α-T was the first that
appeared in the urine of calves. When the calves got older
and turned into young bovines, the concentration of α-T
increased and low amounts of β-T appeared.
In a next step, baseline levels of the control animals
before and during the treatment were compared. Because of
the proven differences between the two groups for α-T and
β-T, data of α-T and β-T obtained in group 2 where
excluded when comparing the baseline levels of the control
animals before and during treatment. Table 5 shows the
mean concentrations, standard deviations, median, mini-
mum, and maximum values of the urinary concentrations of
the free and sulfated forms of DHEA and its metabolites of
all control animals before the start of and during the study.
A small but statistically significant difference in the
concentration of the free and sulfated form of DHEA (p=
0.021) and 5-Andro (p=0.026) was found for which we
have no explanation.
Subsequently, the influence of the oral and intramuscular
treatment with DHEA was investigated, looking at DHEA
Fig. 3 Urinary levels of the sulfated form of DHEA (a), 5-Andro (b), α-T (c) and β-T (d) of the control group (control, n=29), intramuscularly
treated group (IM, n=14) and orally treated group (oral, n=13). o Outlier, * extreme value
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and its metabolites in their sulfated and free form. The
urinary baseline levels of the sulfated form of DHEA and
its metabolites from the control group (control) as well as
the influence of 1 g DHEA orally (oral) or intramuscularly
(IM) administered on urinary DHEA metabolites are
illustrated in Fig. 3. Compared to the control group the
oral treated group differed significantly for the sulfated
forms of DHEA (p=0.000) and 5-Andro (p=0.000). The
intramuscularly treated group differed significantly from
the control group for the sulfated forms of DHEA (p=
0.000), 5-Andro (p=0.000) and α-T (p=0.006). These
statistically proven differences can clearly be seen in
Fig. 3, but when looking at the graphs of α-T, although
not proven, a clear increase of α-T after the oral treatment
Fig. 4 Urinary levels of the free form of DHEA (a), 5-Andro (b), α-T (C), β-T (d) and AED (e) of the control group (control, n=29),
intramuscularly treated group (IM, n=14) and orally treated group (oral, n=13). o Outlier, * extreme value
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can be observed as well. The highest increase was obtained
in the concentration of the sulfoconjugates of DHEA
(DHEAS; >2,000 ng mL−1), followed by the sulfated forms
of 5-Andro and α-T (both around 400 ng mL−1). The 5-
Andro metabolite is the intermediate in the adrenal gland in
the conversion of DHEA to 17β-testosterone immediately
derived by the action of 17β-hydroxysteroid dehydroge-
nase [5], while α-T is considered as the main metabolite of
β-T from the action of 3β-hydroxysteroid dehydrogenase.
There was no increase in the sulfated form of β-T (Fig. 3d)
and no statistical difference between the orally and
intramuscularly treated groups for these sulfated conjugates
could be detected. Figure 4 summarizes the results of the
concentrations of DHEA and its metabolites in the free
form of the three different treatments: control group
(control), orally treated group (oral), and intramuscularly
treated group (IM). The comparison of the concentrations
of DHEA and its metabolites of the different groups in the
free form differed slightly from the sulfated form. Here,
there was a statistically significant difference between the
control group and the orally treated group for DHEA (p=
0.000) and α-T (p=0.000), and when comparing the control
group with the intramuscularly treated group for DHEA
(p=0.000), 5-Andro (p=0.001) and α-T (p=0.000). The
concentration of AED (the metabolite of the ∆4-pathway)
was a bit higher in the orally treated group but could not be
statistically proven. The difference for the intermediate of
the ∆5-pathway (5-Andro) between the oral group and the
control group could also not be proven statistically in
contrast to the comparison of the IM group with the control
group, but Fig. 4b shows that this difference is very small.
Thus, it can be concluded that there was no statistical
difference between the orally and intramuscularly treated
groups for these free target compounds. Comparing the data
from Figs. 3 and 4, it becomes clear that the amounts of the
free forms are relatively low compared to their sulfated
forms.
Searching for a trend in the concentration levels of
DHEA and its metabolites of several days, the correlation
(Spearman’s correlation coefficient R) was tested between
the day of collection of the urine sample and the
concentration of the hormone. This was only performed
for the sulfated forms of DHEA and 5-Andro for the treated
calves, as for the other hormones and the free fraction
concentration levels were too low or the linearity of the
correlation could not be demonstrated by means of a
scatterplot. Figure 5 shows the urinary levels of the sulfated
forms of DHEA and 5-Andro of the separate calves of the
two groups during the seven consecutive days of treatment.
The concentrations of the first day of urine collection of the
second group have been left out, because the urine was
taken after 8 h instead of 24 h like the other days and
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Fig. 5 Urinary levels of DHEA (a) and 5-Andro (b) of the seven consecutive days of treatment from two treated calves of group 1 (filled
triangles) and two treated calves of group 2 (open squares)
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therefore showed much higher concentrations. The concen-
tration of DHEA of the intramuscularly treated calf of
group 2 showed a positive correlation (p<0.05 and R=0.86)
with the days of treatment, meaning that the concentration
increased as the calf was treated more days. The intramus-
cularly treated calf of group 1 did not show this correlation.
We have no straightforward explanation, but the calf in
group 2 was treated in the winter in contrast with the calf in
group 1 that received the treatment in the summertime.
Therefore, the second calf had more adipose tissue,
possibly retaining the DHEA longer and releasing more
DHEA after a few days, resulting in higher DHEAS
concentration in the urine. A positive correlation, but to a
lesser extent, was also seen in this IM treated calf of group
2 for 5-Andro (p=0.05 and R=0.75). In contrast with the
intramuscularly treated group, the orally treated group
showed a steady-state condition.
Conclusions
Sulfates, glucuronides, and free forms were analyzed
separately in order to gather information about the
distribution of DHEA and its metabolites over these three
forms. In general, our results show that DHEAS constitute
the largest proportion of urinary levels of DHEA. This was
also found in humans, where DHEA is rapidly converted
into DHEAS, which can be converted back to DHEA by
peripheral sulfatases [4]. In this way, DHEAS serves as a
large precursor reservoir for the production of androgens
and estrogens in non-reproductive tissues [3]. The free form
of DHEA was present to a much lesser extent than the
sulfated form and DHEA-glucuronides were negligible and
in most cases not quantifiable because concentrations were
below the limit of detection. The same is valid for the
determined DHEA metabolites: mainly present as sulfo-
conjugates, hardly in their free form, and negligible as
glucuronides. There was no statistically significant differ-
ence between the levels of all target hormones in sulfated
and free forms when comparing the orally treated with the
intramuscularly treated group. When comparing the control
group with the treated groups, a statistically significant
difference was obtained for sulfated DHEA and 5-Andro
and the free form of DHEA and α-T for the orally treated
group and sulfated and free form of DHEA, 5-Andro, and
α-T for the intramuscularly treated group. These findings
confirm that administered DHEA metabolizes mainly by
the ∆5-pathway with 5-Andro as the intermediate and that
the metabolization by the ∆4-pathway with AED as the
intermediate is hardly increased.
No elevated levels of sulfated or free β-T were observed
after administering DHEA, either oral or IM. This seems
strange, as levels of α-T were increasing while α-T is
considered as the main metabolite of β-T from the action of
3β-hydroxysteroid dehydrogenase. However, these results
are in accordance with the findings obtained by adminis-
tration of DHEA to the gelding and the mare where there
was a high conversion to 5-Andro and a much lower
conversion to α- and β-T [2]. These results are also
confirmed in humans where ingested DHEA was rapidly
metabolized to 5-Andro [20].
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